Valdespino-Gómez VM

Language: Spanish
References: 8
Page: 264-265
PDF size: 30.68 Kb.

Text Extraction

No abstract.

REFERENCES

1. Kitchen RR, Rozowsky JS, Gerstein MB, Nairn AC. Decoding neuroproteomics: integrating the genome, translatome and functional anatomy. Nature Neurosci. 2014;17:1491-9.

2. Wang E, Zaman N, McGee S, Milanese JS, Masoudi-Nejad A, O’Connor-McCourt M. Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Sem Cancer Biol. 2014;Apr 18 (Epub ahead of print).

3. Garray LA, Verweij J. Precision oncology: an overview. J Clin Oncol. 2014;31:1803-5.

4. [No authors listed.] FDA-approved next-generation sequencing system could expand clinical genomic testing: experts predict MiSeqDX system will make genetic testing more affordable for smaller labs. Am J Med Genet A. 2014;164A:x-xi.

5. Collins FS, Hamburg MA. First FDA authorization for nextgeneration sequencer. N Engl J Med. 2013;369:2369-71.

6. Huser V, Sincan M, Cimino JJ. Developing genomic knowledge bases and databases to support clinical management: current perspectives. Pharmacogenomics Pers Med. 2014;7:275-83.

7. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013;31:1825-33.

8. Doudna J, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.